Our results in vitro show that combining standard of care TMZ therapy with an agent selective for CD44 cell populations and with HA-CPN treatment successfully abrogates viability of TMZ- resistant GBM cells validating this nanoparticle system for further testing in pre-clinical models. This evidence concerns the gene CD44 and glioblastoma.